Challenges in Translating Germinal Stem Cell Research and Therapy.

Stem Cells Int

Stem Cell Institute, James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA.

Published: December 2015

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655299PMC
http://dx.doi.org/10.1155/2016/4687378DOI Listing

Publication Analysis

Top Keywords

challenges translating
4
translating germinal
4
germinal stem
4
stem cell
4
cell therapy
4
challenges
1
germinal
1
stem
1
cell
1
therapy
1

Similar Publications

Glioblastoma (GBM) is the most common malignant primary brain tumor, with a mean survival of less than 2 years. Unique brain structures and the microenvironment, including blood-brain barriers, put great challenges on clinical drug development. Sophoricoside (Sop), an isoflavone glycoside isolated from seeds of Sophora japonica L.

View Article and Find Full Text PDF

Addressing vaccine hesitancy in the training of healthcare professionals: Insights from the VAX-TRUST project.

Public Health Pract (Oxf)

June 2025

Centro Interdisciplinar de Ciências Sociais, Universidade de Évora (CICS.NOVA.UÉvora), Évora, Portugal.

Background: Evidence suggests that healthcare professionals often feel uncomfortable discussing vaccination with patients, largely due to a lack of training on the topic. In line with the scientific evidence gathered from the VAX-TRUST project, it is crucial to invest in training healthcare professionals and developing political measures to effectively address vaccine hesitancy. This paper explores the importance of training healthcare professionals to address vaccine hesitancy and provides concrete strategies for its implementation.

View Article and Find Full Text PDF

Introduction: Assessing the quality of life (QoL) in patients with various diseases is essential for understanding their well-being and guiding clinical management. Dermatological conditions, particularly those affecting the scalp, significantly impact QoL due to their visible nature, which can affect appearance and social interactions. While general QoL instruments like the Dermatology Life Quality Index (DLQI) exist, disease-specific tools like SCALPDEX are necessary for capturing the unique challenges faced by patients with scalp disorders.

View Article and Find Full Text PDF

Airway basal stem cell therapy for lung diseases: an emerging regenerative medicine strategy.

Stem Cell Res Ther

January 2025

Department of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.

Chronic pulmonary diseases pose a prominent health threat globally owing to their intricate pathogenesis and lack of effective reversal therapies. Nowadays, lung transplantation stands out as a feasible treatment option for patients with end-stage lung disease. Unfortunately, the use of this this option is limited by donor organ shortage and severe immunological rejection reactions.

View Article and Find Full Text PDF

Immune responses in children with secondary infection of mycoplasma pneumoniae after COVID-19: focus on eosinophils and IgE.

BMC Infect Dis

January 2025

Luoyang Research Center for Inheritance and Innovation of Chinese Historical Civilization, Luoyang Institute of Science and Technology School of Marxism (LIT), No. 90 Wangcheng Avenue, Luolong District, Luoyang City, Henan Province, China.

Background: The COVID-19 (SARS-CoV-2) epidemic has posed a major challenge to global public health, especially in children. Some children may experience secondary infection with Mycoplasma pneumoniae after SARS-CoV-2 infection, which has attracted widespread attention. Studies have shown that eosinophils play an important role in respiratory tract infections and are involved in regulating immune responses and inflammatory processes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!